Seres Therapeutics Inc

NASDAQ:MCRB  
29.50
+0.11 (+0.37%)
Earnings Announcements

Seres Therapeutics Reports Third Quarter 2020 Financial Results And Provides Business Updates

Published: 11/09/2020 12:23 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates.
Seres Therapeutics Inc - Reported Ecospor Iii Phase 3 Study of Ser-109 Met Primary Endpoint in Q3.
Seres Therapeutics Inc Qtrly Total Revenue $1.4 Million Versus $7.0 Million.
Seres Therapeutics Inc Qtrly Loss per Share $0.36.
Seres Therapeutics Inc - Has Obtained FDA Fast Track Designation for Ser-287 in Active Mild-to-moderate Ulcerative Colitis.
Revenue is expected to be $6.93 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $6.35 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.